Report Library
All Reports2014 BioMedTracker Pre-AASLD Report
*Included free with BioMedTracker Subscription - click here to log inOctober 09, 2014
BioMedTracker will be offering numerous medical meeting conference planners
through 2014 for purchase a la carte, or in a
bundle of several
select conferences. For more information on conference availability and pricing, please
email BioMedTracker or call
BioMedTracker
Client Services at
(858) 200- 2357.
The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) 2014 will be held in Boston, MA from
November 7-11.
We have assembled a sortable, pre-meeting planner listing all presentation titles and affiliated drugs/companies. Additionally, we have
highlighted
abstracts of interest in Hepatitis C, Hepatitis B, and Non-Alcoholic Steatohepatitis (NASH) and included estimated approval timelines for
promising
drugs in mid to late-stage development. A list of meeting catalysts is included at the end of the report as well as high impact catalysts
through the first
half of 2015.
Updated 10/08/14: Late breaking abstract highlights and an in-depth trial analysis performed by Citeline for HCV, HBV, and NASH
were added to
this BioMedTracker Pre-AASLD Report.
We will also be reporting on and analyzing events live from the AASLD conference with
a BMT Post-AASLD Report following the meeting. If there are specific talks, posters, or topics you would like us to follow, or if you would
like
a
copy of the planner in Excel, please e-mail clientservices@pharmaintel.informa.com or call your sales representative.
For the full report, please download the PDF version at the top of this page or contact your
sales representative.
For our disclosures, please read the BioMedTracker Research Standards.
Indications Covered: |
Diabetes Mellitus, Type I
Diabetes Mellitus, Type II Diabetic Nephropathy Hepatic Encephalopathy (HE) Hepatic Fibrosis Hepatitis B (HBV) Treatment (Antiviral) Hepatitis B Prevention (Vaccines, Antiviral) Hepatitis C (HCV) (Antiviral) Hepatitis C Prevention (Vaccines, Antiviral) Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Liver Failure / Cirrhosis Non-Alcoholic Steatohepatitis (NASH) Obesity Solid Tumors |